» Articles » PMID: 38754983

Single-cell Transcriptomes and Chromatin Accessibility of Endothelial Cells Unravel Transcription Factors Associated with Dysregulated Angiogenesis in Systemic Sclerosis

Overview
Journal Ann Rheum Dis
Specialty Rheumatology
Date 2024 May 16
PMID 38754983
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: Vasculopathy emerges early in systemic sclerosis (SSc) and links to endothelial cell (EC) injury and angiogenesis. Understanding EC transcriptomes and epigenomes is crucial for unravelling the mechanisms involved.

Methods: Transcriptomes and chromatin accessibility were assessed by single-cell RNA sequencing and single-nucleus transposase-accessible chromatin sequencing. Immunofluorescent staining of skin and proteomics assay were employed to confirm the altered SSc EC phenotypes. Gain-of-function assay was used to evaluate the effects of ETS transcription factors on human dermal ECs (hDECs).

Results: Both control and SSc ECs shared transcriptomic signatures of vascular linages (arterial, capillary and venous ECs) and lymphatic ECs. Arterial ECs in SSc showed reduced number and increased expression of genes associated with apoptosis. Two distinct EC subpopulations, tip and proliferating ECs, were markedly upregulated in SSc, indicating enhanced proangiogenic and proliferative activities. Molecular features of aberrant SSc-ECs were associated with disease pathogenesis and clinical traits of SSc, such as skin fibrosis and digital ulcers. Ligand-receptor analysis demonstrated altered intercellular networks of SSc EC subpopulations with perivascular and immune cells. Furthermore, the integration of open chromatin profiles with transcriptomic analysis suggested an increased accessibility of regulatory elements for ETS family transcription factors in SSc ECs. Overexpression of ETS genes in hDECs suggested ELK4, ERF and ETS1 may orchestrate arterial apoptosis and dysregulated angiogenesis in SSc.

Conclusions: This study unveils transcriptional and chromatin alterations in driving endovascular dysregulation in SSc, proposing ELK4, ERF and ETS1 as novel targets in ECs for addressing vascular complications in the condition.

Citing Articles

An international perspective on the future of systemic sclerosis research.

Abraham D, Black C, Denton C, Distler J, Domsic R, Feghali-Bostwick C Nat Rev Rheumatol. 2025; 21(3):174-187.

PMID: 39953141 DOI: 10.1038/s41584-024-01217-2.


Characterization of Endothelial Cell Subclusters in Localized Scleroderma Skin with Single-Cell RNA Sequencing Identifies NOTCH Signaling Pathway.

Hutchins T, Sanyal A, Esencan D, Lafyatis R, Jacobe H, Torok K Int J Mol Sci. 2024; 25(19).

PMID: 39408800 PMC: 11477421. DOI: 10.3390/ijms251910473.


Recent Insights into Cellular and Molecular Mechanisms of Defective Angiogenesis in Systemic Sclerosis.

Romano E, Rosa I, Fioretto B, Manetti M Biomedicines. 2024; 12(6).

PMID: 38927538 PMC: 11201654. DOI: 10.3390/biomedicines12061331.

References
1.
Rochette L, Zeller M, Cottin Y, Vergely C . Insights Into Mechanisms of GDF15 and Receptor GFRAL: Therapeutic Targets. Trends Endocrinol Metab. 2020; 31(12):939-951. DOI: 10.1016/j.tem.2020.10.004. View

2.
Goveia J, Rohlenova K, Taverna F, Treps L, Conradi L, Pircher A . An Integrated Gene Expression Landscape Profiling Approach to Identify Lung Tumor Endothelial Cell Heterogeneity and Angiogenic Candidates. Cancer Cell. 2020; 37(3):421. DOI: 10.1016/j.ccell.2020.03.002. View

3.
Pendergrass S, Hayes E, Farina G, Lemaire R, Farber H, Whitfield M . Limited systemic sclerosis patients with pulmonary arterial hypertension show biomarkers of inflammation and vascular injury. PLoS One. 2010; 5(8):e12106. PMC: 2923145. DOI: 10.1371/journal.pone.0012106. View

4.
Chen Z, Morales J, Avci N, Guerrero P, Rao G, Seo J . The vascular endothelial cell-expressed prion protein doppel promotes angiogenesis and blood-brain barrier development. Development. 2020; 147(18). PMC: 7522017. DOI: 10.1242/dev.193094. View

5.
Rice L, Ziemek J, Stratton E, McLaughlin S, Padilla C, Mathes A . A longitudinal biomarker for the extent of skin disease in patients with diffuse cutaneous systemic sclerosis. Arthritis Rheumatol. 2015; 67(11):3004-15. PMC: 5522178. DOI: 10.1002/art.39287. View